



## Targeting p53 Cancer Therapies Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-22	115	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

### Description

The global Targeting p53 Cancer Therapies market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Targeting p53 Cancer Therapies is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Targeting p53 Cancer Therapies is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Targeting p53 Cancer Therapies is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Targeting p53 Cancer Therapies include Alieron Therapeutics, Aprea Therapeutics, Kartos Therapeutics, MultiVir, Rain Oncology, SynerGene Therapeutics, Jc (Wuxi) Company, Sibiono GeneTech and Ascentage Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

### Report Scope

This report quantifies the global Targeting p53 Cancer Therapies market in terms of revenue (US\$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

### Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Targeting p53 Cancer Therapies Market by Company

Alieron Therapeutics

Aprea Therapeutics

Kartos Therapeutics  
MultiVir  
Rain Oncology  
SynerGene Therapeutics  
Jc (Wuxi) Company  
Sibiono GeneTech  
Ascentage Pharma

### **Targeting p53 Cancer Therapies Segment by Type**

Gene Therapy  
Immunotherapy  
Small Molecule Drugs  
Others

### **Targeting p53 Cancer Therapies Segment by Application**

Hospital  
Clinic  
Others

### **Targeting p53 Cancer Therapies Segment by Region**

North America  
United States  
Canada  
Mexico  
Europe  
Germany  
France  
U.K.  
Italy  
Russia  
Spain  
Netherlands  
Switzerland  
Sweden  
Poland  
Asia-Pacific  
China  
Japan  
South Korea  
India  
Australia  
Taiwan  
Southeast Asia  
South America  
Brazil  
Argentina  
Chile  
Middle East & Africa  
Egypt

South Africa

Israel

Türkiye

GCC Countries

## **Key Drivers & Barriers**

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## **Reasons to Buy This Report**

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeting p53 Cancer Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeting p53 Cancer Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeting p53 Cancer Therapies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## **Chapter Outline**

### **Chapter 1:**

Research objectives, research methods, data sources, data cross-validation;

### **Chapter 2:**

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

### **Chapter 3:**

Detailed analysis of Targeting p53 Cancer Therapies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

### **Chapter 4:**

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

### **Chapter 5:**

Production/output, value of Targeting p53 Cancer Therapies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

#### **Chapter 6:**

Consumption of Targeting p53 Cancer Therapies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

#### **Chapter 7:**

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

#### **Chapter 8:**

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

#### **Chapter 9:**

Analysis of industrial chain, including the upstream and downstream of the industry.

#### **Chapter 10:**

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

#### **Chapter 11:**

The main points and conclusions of the report.

# Table of Contents

---

## 1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

---

## 2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
  - 2.2.1 Global Targeting p53 Cancer Therapies Market Size (2021-2032)
  - 2.2.2 Global Targeting p53 Cancer Therapies Sales (2021-2032)
  - 2.2.3 Global Targeting p53 Cancer Therapies Market Average Price (2021-2032)
- 2.3 Targeting p53 Cancer Therapies by Type
  - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
  - 2.3.2 Gene Therapy
  - 2.3.3 Immunotherapy
  - 2.3.4 Small Molecule Drugs
  - 2.3.5 Others
- 2.4 Targeting p53 Cancer Therapies by Application
  - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  - 2.4.2 Hospital
  - 2.4.3 Clinic
  - 2.4.4 Others

---

## 3 Market Competitive Landscape by Manufacturers

- 3.1 Global Targeting p53 Cancer Therapies Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Targeting p53 Cancer Therapies Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Targeting p53 Cancer Therapies Revenue of Manufacturers (2021-2026)
- 3.4 Global Targeting p53 Cancer Therapies Average Price by Manufacturers (2021-2026)
- 3.5 Global Targeting p53 Cancer Therapies Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Targeting p53 Cancer Therapies, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Targeting p53 Cancer Therapies, Product Type & Application
- 3.8 Global Manufacturers of Targeting p53 Cancer Therapies, Established Date
- 3.9 Global Targeting p53 Cancer Therapies Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

---

## 4 Manufacturers Profiled

- 4.1 Alieron Therapeutics
  - 4.1.1 Alieron Therapeutics Company Information
  - 4.1.2 Alieron Therapeutics Business Overview
  - 4.1.3 Alieron Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)
  - 4.1.4 Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  - 4.1.5 Alieron Therapeutics Recent Developments

## 4.2 Aprea Therapeutics

4.2.1 Aprea Therapeutics Company Information

4.2.2 Aprea Therapeutics Business Overview

4.2.3 Aprea Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)

4.2.4 Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio

4.2.5 Aprea Therapeutics Recent Developments

## 4.3 Kartos Therapeutics

4.3.1 Kartos Therapeutics Company Information

4.3.2 Kartos Therapeutics Business Overview

4.3.3 Kartos Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)

4.3.4 Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio

4.3.5 Kartos Therapeutics Recent Developments

## 4.4 MultiVir

4.4.1 MultiVir Company Information

4.4.2 MultiVir Business Overview

4.4.3 MultiVir Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)

4.4.4 MultiVir Targeting p53 Cancer Therapies Product Portfolio

4.4.5 MultiVir Recent Developments

## 4.5 Rain Oncology

4.5.1 Rain Oncology Company Information

4.5.2 Rain Oncology Business Overview

4.5.3 Rain Oncology Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)

4.5.4 Rain Oncology Targeting p53 Cancer Therapies Product Portfolio

4.5.5 Rain Oncology Recent Developments

## 4.6 SynerGene Therapeutics

4.6.1 SynerGene Therapeutics Company Information

4.6.2 SynerGene Therapeutics Business Overview

4.6.3 SynerGene Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)

4.6.4 SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio

4.6.5 SynerGene Therapeutics Recent Developments

## 4.7 Jc (Wuxi) Company

4.7.1 Jc (Wuxi) Company Company Information

4.7.2 Jc (Wuxi) Company Business Overview

4.7.3 Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)

4.7.4 Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio

4.7.5 Jc (Wuxi) Company Recent Developments

## 4.8 Sibiono GeneTech

4.8.1 Sibiono GeneTech Company Information

4.8.2 Sibiono GeneTech Business Overview

4.8.3 Sibiono GeneTech Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)

4.8.4 Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio

4.8.5 Sibiono GeneTech Recent Developments

## 4.9 Ascentage Pharma

4.9.1 Ascentage Pharma Company Information

4.9.2 Ascentage Pharma Business Overview

4.9.3 Ascentage Pharma Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2021-2026)

4.9.4 Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio

4.9.5 Ascentage Pharma Recent Developments

---

## 5 Global Targeting p53 Cancer Therapies Market Scenario by Region

5.1 Global Targeting p53 Cancer Therapies Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Targeting p53 Cancer Therapies Sales by Region: 2021-2032

5.2.1 Global Targeting p53 Cancer Therapies Sales by Region: 2021-2026

5.2.2 Global Targeting p53 Cancer Therapies Sales by Region: 2027-2032

5.3 Global Targeting p53 Cancer Therapies Revenue by Region: 2021-2032

5.3.1 Global Targeting p53 Cancer Therapies Revenue by Region: 2021-2026

5.3.2 Global Targeting p53 Cancer Therapies Revenue by Region: 2027-2032

5.4 North America Targeting p53 Cancer Therapies Market Facts & Figures by Country

5.4.1 North America Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032

5.4.2 North America Targeting p53 Cancer Therapies Sales by Country (2021-2032)

5.4.3 North America Targeting p53 Cancer Therapies Revenue by Country (2021-2032)

5.4.4 United States

5.4.5 Canada

5.4.6 Mexico

5.5 Europe Targeting p53 Cancer Therapies Market Facts & Figures by Country

5.5.1 Europe Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032

5.5.2 Europe Targeting p53 Cancer Therapies Sales by Country (2021-2032)

5.5.3 Europe Targeting p53 Cancer Therapies Revenue by Country (2021-2032)

5.5.4 Germany

5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Russia

5.5.9 Spain

5.5.10 Netherlands

5.5.11 Switzerland

5.5.12 Sweden

5.5.13 Poland

5.6 Asia Pacific Targeting p53 Cancer Therapies Market Facts & Figures by Country

5.6.1 Asia Pacific Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032

5.6.2 Asia Pacific Targeting p53 Cancer Therapies Sales by Country (2021-2032)

5.6.3 Asia Pacific Targeting p53 Cancer Therapies Revenue by Country (2021-2032)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 Taiwan

5.6.10 Southeast Asia

5.7 South America Targeting p53 Cancer Therapies Market Facts & Figures by Country

5.7.1 South America Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032

5.7.2 South America Targeting p53 Cancer Therapies Sales by Country (2021-2032)

5.7.3 South America Targeting p53 Cancer Therapies Revenue by Country (2021-2032)

5.7.4 Brazil

5.7.5 Argentina

5.7.6 Chile

5.8 Middle East and Africa Targeting p53 Cancer Therapies Market Facts & Figures by Country

5.8.1 Middle East and Africa Targeting p53 Cancer Therapies Market Size by Country: 2021 VS 2025 VS 2032

5.8.2 Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2021-2032)

5.8.3 Middle East and Africa Targeting p53 Cancer Therapies Revenue by Country (2021-2032)

5.8.4 Egypt

5.8.5 South Africa

5.8.6 Israel

5.8.7 Türkiye

5.8.8 GCC Countries

---

## 6 Segment by Type

6.1 Global Targeting p53 Cancer Therapies Sales by Type (2021-2032)

6.1.1 Global Targeting p53 Cancer Therapies Sales by Type (2021-2032) & (k units)

6.1.2 Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2032)

6.2 Global Targeting p53 Cancer Therapies Revenue by Type (2021-2032)

6.2.1 Global Targeting p53 Cancer Therapies Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2032)

6.3 Global Targeting p53 Cancer Therapies Price by Type (2021-2032)

---

## 7 Segment by Application

7.1 Global Targeting p53 Cancer Therapies Sales by Application (2021-2032)

7.1.1 Global Targeting p53 Cancer Therapies Sales by Application (2021-2032) & (k units)

7.1.2 Global Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2032)

7.2 Global Targeting p53 Cancer Therapies Revenue by Application (2021-2032)

7.2.1 Global Targeting p53 Cancer Therapies Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2021-2032)

7.3 Global Targeting p53 Cancer Therapies Price by Application (2021-2032)

---

## 8 Value Chain and Sales Channels Analysis of the Market

8.1 Targeting p53 Cancer Therapies Value Chain Analysis

8.1.1 Targeting p53 Cancer Therapies Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Targeting p53 Cancer Therapies Production Mode & Process

8.2 Targeting p53 Cancer Therapies Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Targeting p53 Cancer Therapies Distributors

8.2.3 Targeting p53 Cancer Therapies Customers

---

## 9 Global Targeting p53 Cancer Therapies Analyzing Market Dynamics

9.1 Targeting p53 Cancer Therapies Industry Trends

9.2 Targeting p53 Cancer Therapies Industry Drivers

9.3 Targeting p53 Cancer Therapies Industry Opportunities and Challenges

9.4 Targeting p53 Cancer Therapies Industry Restraints

---

## 10 Report Conclusion

---

## 11 Disclaimer

## List of Tables and Figures

---

### List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Targeting p53 Cancer Therapies Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Targeting p53 Cancer Therapies Sales (k units) of Manufacturers (2021-2026)
- Table 7: Global Targeting p53 Cancer Therapies Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Targeting p53 Cancer Therapies Revenue of Manufacturers (2021-2026)
- Table 9: Global Targeting p53 Cancer Therapies Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Targeting p53 Cancer Therapies Average Price (US\$/unit) of Manufacturers (2021-2026)
- Table 11: Global Targeting p53 Cancer Therapies Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Targeting p53 Cancer Therapies, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Targeting p53 Cancer Therapies, Product Type & Application
- Table 14: Global Targeting p53 Cancer Therapies Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Targeting p53 Cancer Therapies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Alieron Therapeutics Company Information
- Table 19: Alieron Therapeutics Business Overview
- Table 20: Alieron Therapeutics Targeting p53 Cancer Therapies Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 21: Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio
- Table 22: Alieron Therapeutics Recent Developments
- Table 23: Aprea Therapeutics Company Information
- Table 24: Aprea Therapeutics Business Overview
- Table 25: Aprea Therapeutics Targeting p53 Cancer Therapies Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 26: Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio
- Table 27: Aprea Therapeutics Recent Developments
- Table 28: Kartos Therapeutics Company Information
- Table 29: Kartos Therapeutics Business Overview
- Table 30: Kartos Therapeutics Targeting p53 Cancer Therapies Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 31: Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio
- Table 32: Kartos Therapeutics Recent Developments
- Table 33: MultiVir Company Information
- Table 34: MultiVir Business Overview
- Table 35: MultiVir Targeting p53 Cancer Therapies Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 36: MultiVir Targeting p53 Cancer Therapies Product Portfolio
- Table 37: MultiVir Recent Developments
- Table 38: Rain Oncology Company Information
- Table 39: Rain Oncology Business Overview
- Table 40: Rain Oncology Targeting p53 Cancer Therapies Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 41: Rain Oncology Targeting p53 Cancer Therapies Product Portfolio
- Table 42: Rain Oncology Recent Developments
- Table 43: SynerGene Therapeutics Company Information
- Table 44: SynerGene Therapeutics Business Overview
- Table 45: SynerGene Therapeutics Targeting p53 Cancer Therapies Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 46: SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio
- Table 47: SynerGene Therapeutics Recent Developments

- Table 48: Jc (Wuxi) Company Company Information
- Table 49: Jc (Wuxi) Company Business Overview
- Table 50: Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 51: Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio
- Table 52: Jc (Wuxi) Company Recent Developments
- Table 53: Sibiono GeneTech Company Information
- Table 54: Sibiono GeneTech Business Overview
- Table 55: Sibiono GeneTech Targeting p53 Cancer Therapies Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 56: Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio
- Table 57: Sibiono GeneTech Recent Developments
- Table 58: Ascentage Pharma Company Information
- Table 59: Ascentage Pharma Business Overview
- Table 60: Ascentage Pharma Targeting p53 Cancer Therapies Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 61: Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio
- Table 62: Ascentage Pharma Recent Developments
- Table 63: Global Targeting p53 Cancer Therapies Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 64: Global Targeting p53 Cancer Therapies Sales by Region (2021-2026) & (k units)
- Table 65: Global Targeting p53 Cancer Therapies Sales Market Share by Region (2021-2026)
- Table 66: Global Targeting p53 Cancer Therapies Sales by Region (2027-2032) & (k units)
- Table 67: Global Targeting p53 Cancer Therapies Sales Market Share by Region (2027-2032)
- Table 68: Global Targeting p53 Cancer Therapies Revenue by Region (2021-2026) & (US\$ Million)
- Table 69: Global Targeting p53 Cancer Therapies Revenue Market Share by Region (2021-2026)
- Table 70: Global Targeting p53 Cancer Therapies Revenue by Region (2027-2032) & (US\$ Million)
- Table 71: Global Targeting p53 Cancer Therapies Revenue Market Share by Region (2027-2032)
- Table 72: North America Targeting p53 Cancer Therapies Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 73: North America Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units)
- Table 74: North America Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units)
- Table 75: North America Targeting p53 Cancer Therapies Revenue by Country (2021-2026) & (US\$ Million)
- Table 76: North America Targeting p53 Cancer Therapies Revenue by Country (2027-2032) & (US\$ Million)
- Table 77: Europe Targeting p53 Cancer Therapies Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 78: Europe Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units)
- Table 79: Europe Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units)
- Table 80: Europe Targeting p53 Cancer Therapies Revenue by Country (2021-2026) & (US\$ Million)
- Table 81: Europe Targeting p53 Cancer Therapies Revenue by Country (2027-2032) & (US\$ Million)
- Table 82: Asia Pacific Targeting p53 Cancer Therapies Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 83: Asia Pacific Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units)
- Table 84: Asia Pacific Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units)
- Table 85: Asia Pacific Targeting p53 Cancer Therapies Revenue by Country (2021-2026) & (US\$ Million)
- Table 86: Asia Pacific Targeting p53 Cancer Therapies Revenue by Country (2027-2032) & (US\$ Million)
- Table 87: South America Targeting p53 Cancer Therapies Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 88: South America Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units)
- Table 89: South America Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units)
- Table 90: South America Targeting p53 Cancer Therapies Revenue by Country (2021-2026) & (US\$ Million)
- Table 91: South America Targeting p53 Cancer Therapies Revenue by Country (2027-2032) & (US\$ Million)
- Table 92: Middle East and Africa Targeting p53 Cancer Therapies Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 93: Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units)
- Table 94: Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units)
- Table 95: Middle East and Africa Targeting p53 Cancer Therapies Revenue by Country (2021-2026) & (US\$ Million)
- Table 96: Middle East and Africa Targeting p53 Cancer Therapies Revenue by Country (2027-2032) & (US\$ Million)
- Table 97: Global Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (k units)
- Table 98: Global Targeting p53 Cancer Therapies Sales by Type (2027-2032) & (k units)
- Table 99: Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
- Table 100: Global Targeting p53 Cancer Therapies Sales Market Share by Type (2027-2032)
- Table 101: Global Targeting p53 Cancer Therapies Revenue by Type (2021-2026) & (US\$ Million)
- Table 102: Global Targeting p53 Cancer Therapies Revenue by Type (2027-2032) & (US\$ Million)
- Table 103: Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2026)
- Table 104: Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2027-2032)
- Table 105: Global Targeting p53 Cancer Therapies Price by Type (2021-2026) & (US\$/unit)
- Table 106: Global Targeting p53 Cancer Therapies Price by Type (2027-2032) & (US\$/unit)
- Table 107: Global Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (k units)
- Table 108: Global Targeting p53 Cancer Therapies Sales by Application (2027-2032) & (k units)
- Table 109: Global Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026)

- Table 110: Global Targeting p53 Cancer Therapies Sales Market Share by Application (2027-2032)
- Table 111: Global Targeting p53 Cancer Therapies Revenue by Application (2021-2026) & (US\$ Million)
- Table 112: Global Targeting p53 Cancer Therapies Revenue by Application (2027-2032) & (US\$ Million)
- Table 113: Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2021-2026)
- Table 114: Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2027-2032)
- Table 115: Global Targeting p53 Cancer Therapies Price by Application (2021-2026) & (US\$/unit)
- Table 116: Global Targeting p53 Cancer Therapies Price by Application (2027-2032) & (US\$/unit)
- Table 117: Key Raw Materials
- Table 118: Raw Materials Key Suppliers
- Table 119: Targeting p53 Cancer Therapies Distributors List
- Table 120: Targeting p53 Cancer Therapies Customers List
- Table 121: Targeting p53 Cancer Therapies Industry Trends
- Table 122: Targeting p53 Cancer Therapies Industry Drivers
- Table 123: Targeting p53 Cancer Therapies Industry Restraints
- Table 124: Authors List of This Report

## List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Targeting p53 Cancer Therapies Product Image
- Figure 5: Global Targeting p53 Cancer Therapies Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Targeting p53 Cancer Therapies Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Targeting p53 Cancer Therapies Sales (2021-2032) & (k units)
- Figure 8: Global Targeting p53 Cancer Therapies Average Price (US\$/unit) & (2021-2032)
- Figure 9: Gene Therapy Product Image
- Figure 10: Immunotherapy Product Image
- Figure 11: Small Molecule Drugs Product Image
- Figure 12: Others Product Image
- Figure 13: Hospital Product Image
- Figure 14: Clinic Product Image
- Figure 15: Others Product Image
- Figure 16: Global Targeting p53 Cancer Therapies Revenue Share by Manufacturers in 2025
- Figure 17: Global Manufacturers of Targeting p53 Cancer Therapies, Manufacturing Sites & Headquarters
- Figure 18: Global Top 5 and 10 Targeting p53 Cancer Therapies Players Market Share by Revenue in 2025
- Figure 19: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 20: Global Targeting p53 Cancer Therapies Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 21: Global Targeting p53 Cancer Therapies Sales by Region in 2025
- Figure 22: Global Targeting p53 Cancer Therapies Revenue by Region in 2025
- Figure 23: North America Targeting p53 Cancer Therapies Market Size by Country in 2025
- Figure 24: North America Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2032)
- Figure 25: North America Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2032)
- Figure 26: United States Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Canada Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 28: Mexico Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 29: Europe Targeting p53 Cancer Therapies Market Size by Country in 2025
- Figure 30: Europe Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2032)
- Figure 31: Europe Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2032)
- Figure 32: Germany Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: France Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: U.K. Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Italy Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Russia Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Spain Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Netherlands Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Switzerland Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Sweden Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Poland Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Asia Pacific Targeting p53 Cancer Therapies Market Size by Country in 2025
- Figure 43: Asia Pacific Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2032)
- Figure 44: Asia Pacific Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2032)
- Figure 45: China Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: Japan Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 47: South Korea Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: India Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Australia Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Taiwan Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Southeast Asia Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Southeast Asia Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: South America Targeting p53 Cancer Therapies Market Size by Country in 2025
- Figure 54: South America Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2032)
- Figure 55: South America Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2032)
- Figure 56: Brazil Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Argentina Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Chile Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Middle East and Africa Targeting p53 Cancer Therapies Market Size by Country in 2025
- Figure 60: Middle East and Africa Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2032)
- Figure 61: Middle East and Africa Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2032)
- Figure 62: Egypt Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 63: South Africa Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: Israel Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Türkiye Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: GCC Countries Targeting p53 Cancer Therapies Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2032)
- Figure 68: Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2032)
- Figure 69: Global Targeting p53 Cancer Therapies Price (US\$/unit) by Type (2021-2032)
- Figure 70: Global Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2032)
- Figure 71: Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2021-2032)
- Figure 72: Global Targeting p53 Cancer Therapies Price (US\$/unit) by Application (2021-2032)
- Figure 73: Targeting p53 Cancer Therapies Value Chain
- Figure 74: Targeting p53 Cancer Therapies Production Mode & Process
- Figure 75: Direct Comparison with Distribution Share
- Figure 76: Distributors Profiles
- Figure 77: Targeting p53 Cancer Therapies Industry Opportunities and Challenges